Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward
Azer-Cel Safety Profile was Significantly Improved Compared to Prior Cohorts in Patients Dosed Using Optimized Product at Lower Intensity Lymphodepletion; No Grade 3 or Greater Allogeneic CAR T... | May 31, 2023
Michael Amoroso Precision Biosciences Inc Drug Administration Precision Biosciences Chief Executive Officer Potential First In Class Allogeneic
Source: marketscreener.com